Trastuzumab deruxtecan
Modify Date: 2024-01-05 03:34:31
Trastuzumab deruxtecan structure
|
Common Name | Trastuzumab deruxtecan | ||
|---|---|---|---|---|
| CAS Number | 1826843-81-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Trastuzumab deruxtecanTrastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer[1][2]. |
| Name | Trastuzumab deruxtecan |
|---|
| Description | Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Trastuzumab deruxtecan (1 pM-10 nM; 5 days) inhibits the growth of HER2‐positive KPL‐4 cells, with an IC50 of 109.7 pM[2]. Trastuzumab deruxtecan (10 nM; 5 days) shows bystander killing effects in HER2‐negative MDA‐MB‐468 cells[2]. Cell Viability Assay[2] Cell Line: KPL‐4 and MDA‐MB‐468 cells Concentration: 1, 10, 100, 1000, 10000 pM Incubation Time: 5 days Result: Killed both HER2‐positive KPL‐4 cells and HER2‐negative MDA‐MB‐468 cells. |
| In Vivo | Trastuzumab deruxtecan (3 mg/kg; a single i.v.) shows antitumor activity against not only HER2‐positive tumors but also HER2‐negative tumors under the co‐inoculated condition[2]. Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model[3]. Animal Model: Female BALB/c nude mice injected with NCI‐N87 and MDA‐MB‐468‐Luc cells[2] Dosage: 3 mg/kg Administration: A single i.v. Result: Almost all of the HER2‐positive and HER‐negative cells disappeared and there were little or no cancer cells remaining in the tumors. |
| References |
| Storage condition | -20°C |
|---|